TrialPath
Recruiting

DAOIB for the Treatment of Brain Fog

NCT05764538 · Chang Gung Memorial Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial
About this study
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
Eligibility criteria
Inclusion Criteria: * "post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments * physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits * have sufficient education to communicate effectively and are capable of completing the assessments of the study Exclusion Criteria: * history of significant cerebrovascular disease * Hachinski Ischemic Score \> 4 * major neurological, psychiatric or medical conditions other than long COVID-induced cognitive impairments * memantine use (memantine is an NMDAR partial antagonist) * substance (including alcohol) abuse or dependence * delusion, hallucination or delirium symptoms * severe visual or hearing loss * inability to follow the protocol
Study design
Enrollment target: 40 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-02-27
Estimated completion: 2026-06
Last updated: 2026-03-19
Interventions
Drug: DAOIB
Primary outcomes
  • Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24 (week 0, 8, 16, 24)
Sponsor
Chang Gung Memorial Hospital · other
All locations (1)
Kaohsiung Chang Gung Memorial HospitalRecruiting
Kaohsiung City, Taiwan
DAOIB for the Treatment of Brain Fog · TrialPath